Kotani, Daisuke
Yoshino, Takayuki
Kotaka, Masahito
Kawazoe, Akihito
Masuishi, Toshiki
Taniguchi, Hiroya
Yamazaki, Kentaro
Yamanaka, Takeharu
Oki, Eiji
Muro, Kei
Komatsu, Yoshito
Bando, Hideaki
Satake, Hironaga
Kato, Takeshi
Tsuji, Akihito http://orcid.org/0000-0003-4034-1945
Funding for this research was provided by:
Chugai Pharmaceutical Co., Ltd. (None)
Article History
Received: 19 March 2021
Accepted: 30 March 2021
First Online: 21 May 2021
Declarations
:
: D.Kotani received honoraria from Taiho, Ono, Takeda, Lilly, Merck Biopharma, Bristol-Myers Squibb, Chugai, and Sysmex. A.Tsuji received honoraria from Taiho, grants from Taiho, Sanofi, and Bayer. T.Kato received honoraria from Ono, Chugai, Takeda, Taiho, Bayer, and Boehringer-Ingelheim; research funding from Chugai and Takeda. T.Yoshino received grants from Taiho, Sumitomo Dainippon Pharma, Ono, Chugai, Amgen, Parexel International, MSD, Daiichi Sankyo, and Sanofi. H.Satake received honoraria from Chugai, Yakult Honsha, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Merck Biopharma, MSD, Ono, Sanofi, Taiho, Takeda, and Asahi Kasei. H.Bando received honoraria from Taiho and Eli Lilly; grants from AstraZeneca and Sysmex. T.Yamanaka received honoraria and grants from Chugai, Takeda, Boehringer-Ingelheim, Taiho, Daiichi Sankyo, and Bayer; honoraria from Pfizer, Sysmex, HUYA Bioscience International, and Gilead Sciences; grants from Ono, Merck Biopharma, Astellas, and Eli Lilly. Y.Komatsu received honoraria and grants from Eli Lilly, MSD, Taiho, Kyowa Kirin, Ono, Sanofi, and Yakult Honsha; honoraria from Bristol-Myers Squibb, Chugai, EA Pharma, Takeda, Merck Biopharma, Nipro, Pfizer, Sawai, Asahi Kasei, Mitsubishi Tanabe Pharma, Nippon Kayaku, Otsuka, and Novartis Pharma; grants from Sysmex and Astellas. H.Taniguchi received honoraria and grants from Takeda and Taiho; honoraria from Eli Lilly, Chugai, and Ono. K.Muro received research funding from MSD, Daiichi Sankyo, Parexel International, Shionogi, Sumitomo Dainippon Pharma, Sanofi, Pfizer, Mediscience Planning, Solasia Pharma, Merck Biopharma; fees for speakers’ bureau from Ono, Sanofi, Eli Lilly, Chugai, Takeda, Taiho, Bristol-Myers Squibb, and Bayer. K.Yamazaki received honoraria from Daiichi Sankyo, Eli Lilly, Yakult Honsha, Merck Biopharma, Bristol-Myers Squibb, Ono, MSD, Sanofi, Chugai, Takeda, Bayer, and Taiho. E.Oki received lecture fees from Chugai, Taiho, Bayer, Eli Lilly, Takeda, and Ono. M.Kotaka received honoraria from Chugai and Yakult Honsha. A.Kawazoe received honoraria and grants from Taiho and Ono; grants from Sumitomo Dainippon Pharma and MSD. T.Masuishi received honoraria and grants from Ono; honoraria from Takeda, Chugai, Merck Biopharma, Taiho, Bayer, Eli Lilly, Yakult Honsha, Sanofi, and Bristol-Myers Squibb; grants from MSD, Daiichi Sankyo, and Novartis Pharma.
: Before initiation, the principal investigator must consult the Certified Review Board* and receive approval from the study site’s manager and must submit a trial plan to the Minister of Health, Labor and Welfare. * An application for this study will be submitted to the following Certified Review Board: Shizuoka Cancer Center Institutional Review Board (Certification No. CRB4180010).
: All participants provided written and informed consent before enrollment.
: Not applicable.